Literature DB >> 24728944

A long-term follow-up and comprehensive observation of risk and prognosis factors of recurrence and survival after resection of hepatocellular carcinoma.

Lei Hu1, Feng Xue, Yunyun Li, Minhua Shao, Yanfu Sun, Gongtian Wei.   

Abstract

Although HBV, liver function and tumor characteristics were proven as hepatocellular carcinoma (HCC) prognosis-related, no large-scale and long-term follow-up studies have ever given robust evidence about prognosis predictive effect and contribution to different stage of postoperation. In this study, we evaluated the influence of above index on overall survival (OS) and disease-free survival (DFS) and other clinical data in a rather large population and long-term follow-up. Our study consisted of 1,326 HCC patients who underwent radical resection from 1996 to 2010. Epidemiology, clinical and prognosis data were analyzed. Risk factors of OS and DFS were explored. Cumulative survival comparison between groups was performed with log-rank. Multivariate analysis for independent prognostic factors was determined by Cox proportional hazards model. HBsAg status was a universal factor of HCC recurrence, while preoperational albumin (ALB) and portal vein tumor thrombus (PVTT) affected survival during the whole lifetime. Early stage recurrence was associated with capsule intact [OR (95 %) = 1.54,1.12-2.12, p = 0.009], preoperational alpha-fetoprotein (AFP), TNM and BCLC stages were the most important prognosis factors of recurrence in the early 5 years and PVTT affected the rest time. Survival was mainly associated with tumor characteristic and ALB. Short-time survival was affected with age and AFP, while BCLC was related with the long-time survival. We confirmed that during different periods after resection, factors affecting prognosis did not remain unchanged. Liver function and tumor characteristic affected DFS and OS the whole time, especially the early recurrence. However, HBV infection situation was associated with later recurrence. PVTT showed an opposite effect between early and later recurrence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24728944     DOI: 10.1007/s12013-013-9813-3

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  8 in total

1.  Malic enzyme 1 induces epithelial-mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma.

Authors:  Duo Wen; Dongli Liu; Jun Tang; Lili Dong; Yang Liu; Zhonghua Tao; Jinliang Wan; Dongmei Gao; Lu Wang; Huichuan Sun; Jia Fan; Weizhong Wu
Journal:  Tumour Biol       Date:  2015-03-10

2.  Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients.

Authors:  T T Zhang; X Q Zhao; Z Liu; Z Y Mao; L Bai
Journal:  Clin Transl Oncol       Date:  2015-11-17       Impact factor: 3.405

3.  Reduced red blood cell count predicts poor survival after surgery in patients with primary liver cancer.

Authors:  Xiaomeng Xie; Mingjie Yao; Xiangmei Chen; Weiquan Lu; Quanjun Lv; Kaijuan Wang; Ling Zhang; Fengmin Lu
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

4.  Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio in Hepatocellular Carcinoma Patients Treated with Liver Transplantation.

Authors:  Hui Li; Li Wang; Liang Chen; Hui Zhao; Jianye Cai; Jia Yao; Jun Zheng; Yang Yang; Genshu Wang
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

5.  Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research.

Authors:  Xiaoguang Wang; Xiaodan Yang; Fei Chen; Shaohan Wu; Zhengwei Song; Jianguo Fei
Journal:  Can J Gastroenterol Hepatol       Date:  2021-01-08

6.  Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis.

Authors:  Feng Xia; Peng Zhu; Xiao-Ping Chen; Bi-Xiang Zhang; Ming-Yu Zhang
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

Review 7.  Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression.

Authors:  Wei Li; Jun Han; Hong Wu
Journal:  Chronic Dis Transl Med       Date:  2016-11-09

8.  INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Xiaodong Song; Yong He; Huihong Liang; Menling Han; Zili Shao
Journal:  BMC Surg       Date:  2020-08-01       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.